0.728

0.42% -0.0031

Aprea Therapeutics Inc (APRE)

Overview News Price History Financials Discussions Forecast Stock Split

Aprea Therapeutics Inc stock is traded at $0.728, with a volume of 997. It is down -0.42% in the last 24 hours and down -10.99% over the past month. Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Previous Close:

$0.7311

Open:

$0.7313

24h Volume:

997

Relative Volume:

0.00

Market Cap:

$8.37M

Revenue:

$488.20K

Net Income/Loss:

$-13.04M

P/E Ratio:

-0.34

EPS:

-2.141

Net Cash Flow:

$-13.57M

1W Performance:

-4.84%

1M Performance:

-10.99%

6M Performance:

-49.44%

1Y Performance:

-69.15%

1-Day Range:

$0.7313

1-Week Range:

$0.72

$0.84

52-Week Range:

$0.548

$2.65

Aprea Therapeutics Inc Stock (APRE) Company Profile

Name

Aprea Therapeutics Inc

Sector

Healthcare (1121)

Industry

Biotechnology (620)

Phone

215-948-4119

Address

3805 OLD EASTON ROAD, DOYLESTOWN, MA

Employee

Twitter

Next Earnings Date

2026-03-24

Latest SEC Filings

APRE's Discussions on Twitter

Compare APRE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APRE Aprea Therapeutics Inc	0.7313	8.37M	488.20K	-13.04M	-13.57M	-2.141
VRTX Vertex Pharmaceuticals Inc	453.48	114.72B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	743.04	78.67B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	685.06	42.38B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	314.65	41.75B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	282.42	31.33B	5.36B	287.73M	924.18M	2.5229

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-28-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Jun-22-20	Initiated	H.C. Wainwright	Neutral
Apr-21-20	Initiated	Robert W. Baird	Outperform
Oct-28-19	Initiated	JP Morgan	Neutral
Oct-28-19	Initiated	Morgan Stanley	Equal-Weight
Oct-28-19	Initiated	RBC Capital Mkts	Outperform

View All

Aprea Therapeutics Inc Stock (APRE) Latest News

Mar 17, 2026

Aprea Therapeutics (APRE) files amendment adding EisnerAmper consent to registration - Stock Titan

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc Stock (APRE) Company Profile

Compare APRE vs VRTX, REGN, ARGX, ALNY, ONC

Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades

Aprea Therapeutics Inc Stock (APRE) Latest News

Aprea Therapeutics (APRE) files amendment adding EisnerAmper consent to registration - Stock Titan

Aprea Therapeutics (APRE) Projected to Post Quarterly Earnings on Tuesday - Defense World

Aprea Therapeutics (NASDAQ: APRE) CEO receives new equity awards - Stock Titan

Equity awards lift Aprea (NASDAQ: APRE) CFO Hamill’s share stake - Stock Titan

H.C. Wainwright Maintains Buy on APRE Aprea Therapeutics Inc March 2026 - Meyka

Aprea Therapeutics Reports 2025 Financial Results and Clinical Progress for APR-1051 WEE1 Inhibitor in Endometrial Cancer - Minichart

H.C. Wainwright reiterates Aprea stock rating, keeps $4 target - Investing.com

Aprea reports second partial response in phase 1 APR-1051 trial - MSN

Aprea Highlights Early APR-1051 Data and Financial Update - TipRanks

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - Bitget

Aprea Therapeutics Q4 eps usd -0.32 - marketscreener.com

[10-K] Aprea Therapeutics, Inc. Files Annual Report | APRE SEC FilingForm 10-K - Stock Titan

Aprea Therapeutics 10-K: $0.286M Grant Revenue, Loss per Share $(1.93) - TradingView

APRE: Clinical progress and improved financials position the company for key milestones in 2026 - TradingView

Aprea Therapeutics (Nasdaq: APRE) posts 2025 loss and oncology pipeline update - Stock Titan

Aprea Therapeutics Q4 EPS $(0.32) Misses $(0.... - Benzinga

Aprea Therapeutics Q4 net loss narrows as R&D costs fall - TradingView

Experimental endometrial cancer drug cut tumors by half in 2 patients - Stock Titan

Plus: Q4 Earnings Snapshot - Barchart.com

APRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Aprea Therapeutics stock rises after company reports second unconfirmed case of tumor reduction in trial - MSN

Published on: 2026-03-07 13:05:37 - baoquankhu1.vn

Stock Report: Is Aprea Therapeutics Inc backed by strong institutional buyingJuly 2025 Recap & Daily Profit Maximizing Trade Tips - baoquankhu1.vn

Aprea Therapeutics Showcases Emerging Clinical Data for WEE1 Inhibitor APR-1051 - Barchart.com

Aprea Reports Second Partial Response in Phase 1 APR-1051 Trial - MyChesCo

Aprea to Present at Oppenheimer Healthcare Conference - MyChesCo

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Aprea Therapeutics (NASDAQ:APRE) Upgraded at Zacks Research - Defense World

Aprea reports second partial response in endometrial cancer trial - Investing.com South Africa

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Aprea Therapeutics announces additional positive clinical activity for Wee1 inhibitor, APR-1051 - marketscreener.com

Aprea Therapeutics Announces Additional Positive Clinical Activity For Wee1 Inhibitor, APR-1051 - TradingView

Aprea Highlights Encouraging Phase 1 Data for APR-1051 - TipRanks

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - The Manila Times

Experimental cancer drug shrinks endometrial tumor by 50% in early trial - Stock Titan

Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - VISTA.Today

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget

APREAprea Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

IPO Launch: Is Aprea Therapeutics Inc gaining market shareWeekly Market Summary & Daily Profit Maximizing Tips - baoquankhu1.vn

Will Aprea Therapeutics Inc. stock hit new highs in YEARQuarterly Trade Summary & Weekly High Return Forecasts - mfd.ru

Is Aprea Therapeutics Inc. a potential multi baggerJuly 2025 Rallies & Expert-Curated Trade Recommendations - mfd.ru

Will Aprea Therapeutics Inc. stock go up in YEARJuly 2025 Sentiment & High Conviction Investment Ideas - mfd.ru

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growthboerse.de - boerse.de

Aprea taps veteran oncologist as clinical momentum builds for lead cancer drug - MSN

Aprea Therapeutics strengthens global patent portfolio in DNA Damage Response (DDR) cancer therapeutics - marketscreener.com

Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics - TradingView

Aprea Therapeutics Expands Global Patent Portfolio for WEE1 and ATR Programs, Securing Exclusivity Through 2045 - Quiver Quantitative

Aprea Therapeutics Inc Stock (APRE) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to APRE